Ma et al. described two cases of R/R AML patients, relapsed after HCT and failing multiple salvage therapies including CD38-directed CAR-T cells, that were successfully treated with PD1-silenced anti-CCL1 CAR-T cells: both patients achieved a molecular CRi 28 days after CAR-T cell infusion and maintained continuous remission for 8 and 3 months, respectively [128]. The gene discussed is CD38; the disease is acute myeloid leukemia.